This week’s news from the life sciences includes Eli Lilly's investment in a Cambridge-Singapore biotech, Stealth ...

RNA specialist Wave Life Sciences has been told by Takeda that the Japanese drugmaker is to bring to an end the last facet of ...

HC Wainwright has initiated coverage on Alumis Inc. (NASDAQ:ALMS), a clinical-stage biopharmaceutical company developing oral ...

Wave claims this is the first clinical data with a therapeutic RNA-editing drug in humans, an achievement that boosted its ...

The vaccine began being administered through the public health sysem in February this year. It was prioritized for children ...

Cerevance, a clinical-stage biopharmaceutical company advancing multiple cell type-specific therapies for the treatment of ...

Leadership succession strategy, which includes a new CFO appointment and creation of a new CCO role is expected to bolster ...

Wave Life Sciences reports that it has successfully carried out RNA editing in two patients with alpha-1 antitrypsin ...

Wave Life Sciences' WVE-006 study shows significant promise in treating alpha-1 antitrypsin deficiency. Learn more about WVE ...

A diet high in ultraprocessed foods can raise the relapse risk in patients with Crohn’s disease who are in remission, with ...